08 May, 2017
Four analysts have provided estimates for ACADIA Pharmaceuticals' earnings. The company presently has an average rating of "Buy" and an average target price of $57.91. They now have a Dollars 53 price target on the stock.
Several equities analysts have commented on the company. Mizuho reiterated a "buy" rating and issued a $52.00 price objective (up from $45.00) on shares of Acadia Healthcare Company in a report on Monday, February 27th. Jefferies Group LLC set a $55.00 price target on Acadia Healthcare Company and gave the company a "buy" rating in a research report on Tuesday, December 20th. Zacks Investment Research upgraded Acadia Healthcare Company from a "sell" rating to a "hold" rating in a report on Friday, April 28th. Cantor Fitzgerald reiterated a "hold" rating and issued a $45.00 price objective on shares of Acadia Healthcare Company in a report on Wednesday, April 26th.
With these kinds of figures it is worthy to note that Acadia Healthcare Company, Inc. Parametric Assocs Limited Liability Company accumulated 126,308 shares or 0.01% of the stock. The median target of analyst views collected by Yahoo Finance was as much as $6.73 below ACHC's recent stock price. (NASDAQ:ACHC) stock went gone down with a prior 52-week high of $63.67.During the session shares traded on above-average volume. The Jgp Global Gestao De Recursos Ltda holds 28,913 shares with $834,000 value, up from 11,696 last quarter.
Acadia Healthcare Company, Inc.'s Quick Ratio shows the value of 0. During the same quarter past year, the business posted $0.55 earnings per share. ACADIA Pharmaceuticals's quarterly revenue was up 70488.2% compared to the same quarter previous year. Earnings, with 16 analysts believing the company would generate an Average Estimate of $0.65.
09/15/2016 - Acadia Healthcare Company, Inc. had its " rating reiterated by analysts at Robert W. Baird. If you are accessing this piece on another site, it was stolen and republished in violation of US & worldwide trademark and copyright law. (ACHC). A frequently used tool among technical stock analysts is the moving average. The Weekly and Monthly Volatility stands at 2.31% and 3.12%. Following the sale, the chief operating officer now directly owns 137,204 shares in the company, valued at $6,095,973.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
In related news, VP Randall P. Goldberg sold 914 shares of the business's stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $39.77, for a total value of $6,265,365.80. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company's stock valued at $155,000 after buying an additional 510 shares during the period. The disclosure for this sale can be found here. The third largest holder is Jpmorgan Chase & Co, which now holds $335.98 million worth of this stock and that ownership represents almost 8.66% of its market capitalization. Price T Rowe Associates Inc /Md/ owns $525.55 million in Acadia Healthcare Company, Inc., which represents roughly 13.55% of the company's market cap and approximately 12.32% of the institutional ownership. (NASDAQ:ACHC) now have an ABR of 1.33.which is marked on a basic 1 to 5 scale, where 1 stands for a Strong Buy and 5 represents Strong Sell.
Acadia Healthcare Company, Inc.'s 52-week high is now at -29.04% and the 52-weel low is at 38.84%. Suntrust Banks Inc. now owns 5,317 shares of the company's stock worth $262,000 after buying an additional 490 shares in the last quarter. Suntrust Banks Inc. raised its stake in shares of Acadia Healthcare Company by 10.2% in the third quarter.
In other news, COO Ronald Morgan Fincher sold 86,483 shares of the stock in a transaction dated Monday, May 1st. Can raised its position in Acadia Healthcare Company by 84.5% in the third quarter. Finally, Manning & Napier Advisors LLC raised its position in Acadia Healthcare Company by 52.6% in the third quarter. Over the last 90 days, insiders have sold 92,322 shares of company stock worth $4,104,756. As of December 31, 2016, the Company had operated 573 behavioral healthcare facilities with approximately 17,100 beds in 39 states, the United Kingdom and Puerto Rico. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
